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ABSTRACT
People who suffers renal angiomyolipoma (AML) has a low quality of life. It is widely known that genetic factors
including TSC2 mutation contribute to certain populations of renal AML-bearing patients. In this study, we are
the first to identify novel TSC2 mutations in one Chinese renal epithelioid AML patient: c.2652C>A; c.2688G>A
based on sequencing result frombiopsy tissue. These two somaticmutations cause a translational stop of TSC2,
which leads to mTORC1 activation. Given the fact that activation of mTORC1 ensures cell growth and survival,
we applied its inhibitor, FDA-approved everolimus, to this woman. After months of treatment with everolimus,
Computer-Tomography (CT) scan results showed that everolimus successfully reduced tumor growth anddistal
metastasis and achieved partial response (PR) to everolimu according to Response Evaluation Criteria in Solid
Tumors (RECIST version 1.1). Further Blood Routine Examination results showed the concentration of red cell
mass, hemoglobin, white blood cell (WBC), platelets and hematocrit (HCT) significantly returned to normal
levels indicating patients with these two TSC2 mutations could be effectively treated by everolimus.
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Introduction
With an approximate 1–2 percent incidence, angiomyolipoma
(AML) is considered as a mesenchymal tumor frequently
detected in the kidney consisting of smooth-muscle-like
cells, adipocyte-like cells, and epithelioid cells.1-3 Typically,
AMLs can be classified into classic variant and epithelioid
variant based on the percentage of epithelioid cells.
Characterizations of classic variant include abnormally thick-
walled vessels and sparse epithelioid cells (usually less than
10 percent).4,5 However, the epithelioid variant always has
more than 10 percent of epithelioid cells, which are distin-
guished by abundant eosinophilic and granular cytoplasm. In
clinical, more attention has been paid on epithelial variant
because it can undergo malignant transformation.
Approximate 20% of renal AMLs is associated with tuberous
sclerosis complex (TSC), an autosomal dominant multisystem
disorder caused by the mutation of either TSC1 or TSC2.6,7
TSC2/TSC1 complex is one central regulator of mTORC1 signal-
ing pathway.8,9 TSC2 complexes with TSC1 to inhibit mTORC1
signaling via driving Rheb into GDP-bound state, which acts as
GTPase to activate mTORC1 when it is in GTP-bound state.10,11
In the response to environmental stresses such as nutrients, oxy-
gen, DNA damage, and growth factors, mTORC1 signaling is
activated and controls cell growth and survival.12,13 In addition,
mTORC1 is also implicated into cancer development due to its
regulation on cell proliferation, angiogenesis, and metastasis.14-16
Therefore, mTORC1 is an appealing therapeutic target in clinic.
Indeed, mTORC1 inhibitors such as deforolimus, everolimus and
temsirolimus have been prevalently assessed in various cancers,
alone or in combination with other targeted therapies or
chemotherapies.17,18 Importantly, everolimus and temsirolimus
were recently approved by the FDA for the treatment of renal
cell carcinoma.
Here, we report a rare case of epithelioid renal AML.
Biopsy tissue sequencing revealed that the patient carried
two Somatic TSC2 mutation. Both mutations result in
a translational stop of TSC2, which leads to mTORC1 activa-
tion. For this reason, FDA-approved eveolimus was admini-
strated to control tumor progression.
Materials and methods
Fresh clinical kidney tumor tissues were collected according
to the ethical guidelines of the Declaration of Helsinki (1975)
and the Institutional Medical Ethics Committee of Xiamen
University. Pathological diagnosis of BCa was verified by at
least two pathologists.
DNA extraction
Tumor genomic DNA was extracted from AML biopsy tissue
using the QIAamp DNA Micro Kit (Cat#56304, Qiagen) to
identify potential mutations. DNA concentration was mea-
sured using a Qubit fluorometer (Cat#Q33216, Invitrogen)
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and the Qubit dsDNA HS (High Sensitivity) Assay Kit
(Cat#Q32854, Invitrogen). Total DNA was analyzed
by second-generation sequencing for 1021 cancer-related
genes. The loci of mutation in TSC2 was further validated
by first-generation sequencing.
Targeted capture and next-generation sequencing
The next-generation sequencing of the tumor DNA was per-
formed by Geneplus–Beijing Institute (Beijing, China). Firstly,
about 1 μg of DNA was sheared by an ultrasonoscope to generate
DNA fragments about 250 bps in length followed by end repair,
A tailing, and ligation to the Illumina-indexed adapters. Then, the
fragments were subjected to prepare library constructions by
using the IlluminaTruSeqDNALibrary PreparationKit according
to Manufacturer’s instruction. Target enrichment was performed
with a custom SeqCap EZ Library (Roche NimbleGen, Madison,
WI, USA). Capture hybridization was carried out according to the
manufacturer’s protocol. Capture probes were designed to cover
coding sequences or hot exons of 1,021 genes frequently mutated
in solid tumors as shown in Table S1.19 DNA sequencing was
carried out with theHiSeq 3000 Sequencing System (Illumina, San
Diego, CA) with 2 × 100-bp paired-end reads. Targeted capture
sequencing revealed a mean effective depth of coverage of 671 ×.
RT-PCR and first-generation sequencing
For the Sequencing verification of TSC2, the primer pairs
(Forward: CAGTATGCCAGTGTGTTCGCC; Reverse:
AGTGAGCACACCCAGACAGTG) were designed based on
the genomic sequences from the NCBI (https://www.ncbi.
nlm.nih.gov/). A 641 bp of TSC2 DNA fragment were PCR-
amplified using genomic DNA prepared from AML biopsy
tissue with Pyrobest DNA Polymerase (Cat#DR500A,
TaKaRa). The resultant DNA fragments were subjected to
first-generation sequencing.
Frozen section and H & E staining
Briefly, the dissected biopsy tissue was mounted in OCT
embedding compound and frozen at −20 to −80°C. Then, 10
µm thick tissue sections were made using a cryostat. Thaw-
mount the sections onto gelatin-coated histological slides,
which were pre-coated with gelatin to enhance adhesion of
the tissue. H & E staining was performed on the frozen
sections using Hematoxylin and Eosin reagents.
Immunohistochemistry staining and TFE3 FISH analysis
Antigen retrieval was performed on the deparaffinized and rehy-
drated tissue sections by boiling them in a citrate buffer (pH 6.0)
for 30 min. After cooled down, the sections were treated with
a peroxidase blocking buffer for another 30 min. After incuba-
tion with the blocking buffer (5% normal goat serum in PBS) for
1 h at room temperature, the sections were blotted with primary
antibodies: HMB45 (Cat#MA1-34759, Thermo Fisher), Melan
A (Cat#MA5-15237, Thermo Fisher), α-Smooth Muscle Actin
(α-SMA) (Cat#14-9760-82, Thermo Fisher), PAX-8 (Cat#RAB-
0657, MXB Biotechnologies, Fuzhou, China), Pan-Cytokeratin
(Cat#RAB-0050, MXB Biotechnologies) and TFE3 (Cat#PA5-
54909, Thermo Fisher). Then, biotin-labeled secondary antibody
was added for another 30 min, followed by 30 min streptavidin
incubation and signals were determined by DAB staining. TFE3
FISH detection was performed according to the manufacturer’s
instructions as described.20
Western blot analysis
Tissues were lysed in an ice-cold RIPA lysis buffer. 40 µg
protein were loaded for electrophoresis on 8% denaturing
SDS-PAGE gels. After transferred to PVDF membrane, the
blots were probed with the primary antibodies overnight at 4°
C, followed by incubation with secondary antibodies at room
temperature for 2 h. The following primary antibodies were
used: mTOR (Cat#2983, Cell Signaling), TSC2 (Cat#3612, Cell
Signaling) and GAPDH (Cat#5174, Cell Signaling).
Results
In September 2016, one 46-year-old woman with pain in
abdomen was referred to Department of Urology Surgery,
The First Affiliated Hospital of Xiamen University. Image
from Computer-Tomography (CT) scan showed that a huge
mass existed on the dorsolateral surface of the left kidney with
uneven density, which was suspected to be renal carcinoma
(data not shown). Then, this patient was undergone radical
nephrectomy surgery on 27 September and the size of the
tumor tissue is about 10 × 9.5 × 6 cm (Figure 1(a)).
Subsequently, the tumor tissue was subjected to histological
analysis. Unexpectedly, an examination of frozen section
revealed that this woman had renal AML, with densely eosi-
nophilic cytoplasm and large hyperchromatic nucleus under
the microscope (Figure 1(b)). Additionally, immunochemical
staining with associated antibodies showed that this woman
currently suffered from renal epithelioid AML (data not
shown). We checked the medical history, CT and skin exam-
ination results and excluded the possibility of mental deficien-
cies and sebaceous adenoma in this patient. Together these
results showed that this patient suffered from renal epithelioid
AML rather than Tuberous Sclerosis Complex. One year later
at 17 December 2018, this patient went back to our hospital
for check. Surprisingly, we found that her tumor invaded into
peritoneal and pelvic area based on the result from CT scan
(Figure 4(a)). A biopsy tissue was subjected to histological
analysis. Consistent with previous examination, H &
E staining results revealed that this woman had renal AML
(Figure 1(b)). Additionally, immunochemical staining with
associated antibodies showed that the isolated tissue was posi-
tive for Melan A, HMB45, and TFE3, which are specific
biomarkers for renal epithelioid AML (Figure 1(c)).
Recently, Maria S. Tretiakova et al. reported that
Eosinophilic solid and cystic renal cell carcinoma (ESC-
RCC) is morphologically similar to a subset of tuberous
sclerosis complex (TSC)-associated tumors and can mimic
renal epithelioid AML.21 Their further immunostaining ana-
lysis showed that ESC-RCC was positive for CK20 and mela-
nocytic markers Melan-A, Cathepsin-K or HMB45, as well as
PAX-8, whereas pan-cytokeratin and SMA were negative.
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Compared with all ESC-RCC, eAML cases were positive for
either Melan-A or HMB45, most were positive for SMA (3/4),
whereas all were negative for pan-cytokeratins AE1/AE3.21
Consistent with their results, our further immunostaining
analysis showed that SMA was positively expressed, whereas
PAX-8 and pan-cytokeratin were negatively expressed in this
case suggesting that this patient was eAML certainly. To
further exclude the possibility of renal cell carcinoma asso-
ciated with Xp11.2 translocation/TFE3 gene fusions, we per-
formed TFE3-FISH analysis. TFE3-FISH result showed that
Figure 1. Identification of epithelioid AML in one Chinese woman. (a) Tumor mass after radical nephrectomy surgery. (b) H & E staining analysis of tumor tissues. (c-e)
Immunohistochemistry analysis of tumor tissues. The patient’s biopsy tumor tissues were stained with antibodies against HMB45, Melan A, SMA, TFE3, PAX-8, and CK (Pan).
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the rearrangements of TFE3 are rare and lower no more than
5% (Figure 2). Our targeted capture sequencing also con-
formed our FISH result (Table 1). Together, all these findings
suggest that this patient currently suffered from kidney
epithelioid AML.
AML is observed in 75% patients with tuberous sclerosis com-
plex (TSC), which is caused by either TSC1 or TSC2mutation. To
identify which pathological mutation is responsible for this case,
we screened a wide panel of 1021 cancer-associated genes using
the biopsy tissue and found two somatic mutations in TSC2 and
one somatic mutation in LRP1B, however, no germline mutation
was detected (Table 1). One mutation in TSC2 is c.2652C>A, in
which cytosine is replaced by adenine at position of 2652. Another
one in TSC2 is c.2688G>A, in which a stop code was introduced at
896 amino acid residue. The stop code introduced at these two
sites would lead to a truncated TSC2 transcript as indicated in
Figure 3(a). Furthermore, RT-PCR was performed to amplify the
TSC2 DNA fragment (Figure 3(b)). Indeed, sequencing analysis
confirmed these two mutations (Figure 3(c,d)). On the other
hand, Western blot results showed that the mutation at these
two sites resulted in remarkably reduced expression levels of full-
length TSC2 in AML tissue (Figure 3(e)). By contrast, mTOR was
significantly up-regulated compared with control tissues
(Figure 3(e)). Therefore, the translational premature of TSC2
causes a hyper-active mTORC1 signaling, which in turn promotes
tumor cell growth and survival.
Figure 2. FISH analysis for TFE3 in tumor tissues. Statistical analysis showed that
the percent of TFE3 fusion cells was less than 5% suggesting this patient was
not Xp11.2 translocation renal cell carcinoma.
Table 1. TSC2 and LRP1B mutations analyzed by Next-generation DNA sequencing.
Gene
Base
Alteration
Amino Acid
Alteration Region
Mutation
Frequency
TSC2 c.2652 C > A p. Y884* Exon 24 7.0%
TSC2 c.2688 G > A p. W896* Exon 24 11.0%
LRP1B c.6419 G > A p.R2140K Exon 40 7.6%
Figure 3. Mutations in TSC2 resulted in a truncated transcript and reduced protein levels. (a) Diagram of wild type (WT) and mutant TSC2 proteins, as predicted from
cDNA and genomic sequencing in this AML patient. (b) RT-PCR showed the mutation region of TSC2 DNA in this patient. (c-d) First-generation sequencing to
determine the loci of TSC2 mutations. (e) Western blotting showed that TSC2 expression was reduced in this patient, whereas mTOR was over expressed in tumor
tissue. GAPDH served as a loading control.
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Everolimus was approved by FDA to treat renal cell carci-
noma for its efficient inhibition of mTORC1 activity. We
sought to explore whether everolimus could ameliorate the
progression of this type of AML. This patient was taken
everolimus on 2 January 2018 and was checked every month
by CT scanning. The images showed that the tumor mass was
significantly reduced after drug administration (Figure 4(a–
d)). After 4 weeks of drug administration, the tumor size was
significantly reduced from 12.74 × 8.47 cm to 9.46 × 5.12 cm
(Figure 4(a,b)). The sum of longest diameters decreased by
30.3%. According to Response Evaluation Criteria in Solid
Tumors (RECIST version 1.1),22 the patient achieved
a partial response (PR) to everolimus. Four months after
drug administration, the tumor size was significantly reduced
to 8.25 × 4.6 cm and the sum of longest diameters decreased
by 38.6% (Figure 4(d)). In addition, we evaluated her blood
cells before and after everolimus uptake. Interestingly, this
patient with lower values of red cell mass (*1012/L),
Hemoglobin (g/L) and hematocrit (HCT) before drug admin-
istration significantly improved and turned to normal levels
after everolimus uptake (Figure 5(a–c), Table 2). While white
blood cells (*1012/L) and Platelets (*1012/L) also returned to
normal levels from abnormal (Figure 5(d,e), Table 2). Other
blood routine index such as mean corpuscular hemoglobin
concentration (MCHC, g/L), reticulocyte (RET, %), immature
reticulocyte fraction (IRF, %), high light scattering reticulo-
cyte (HLR, %), lymphocyte (LY, %), basophil (BA, %), mono-
cyte (MO, %) and eosinophil (EO, %) were also returned to
normal value from abnormally levels (Table 2). Blood cell
analysis suggested her health status significantly got
improved. Collectively, all these data indicate that the epithe-
lioid AML in this woman was resulted from gene mutation of
TSC2 and was successfully controlled by administration of
everolimus.
Discussion
Renal AMLs are tightly related with tuberous sclerosis complex
TSC1/2.1 Here, we identified two mutations (c2652C>A;
c2688G>A) in TSC2 according to our biopsy sequencing result.
To our knowledge, our report about TSC2mutation is novel even
though numerous mutations in TSC2 have been reported. These
two mutations cause translational stop of TSC2, leading to super
activation of mTORC1 signaling so that this AMLwas sensitive to
everolimus treatment. Indeed, administration of everolimus into
this woman evidently reduced the progression of renal AML with
these two TSC2 mutations. Early reports have been identified
TSC2 mutations in AMLs such as c.1593C>T, c.3094C>T,
c.4968C>T, c.228C>T, c.4780C>T and so on.23-26 These muta-
tions either introduced an early termination code in TSC2 or
caused conformational change of TSC2. Here, our identified
mutations (c2652C>A; c2688G>A) in TSC2 led to its reduced
expression, which in turn triggeredmTORC1 activation via main-
taining Rheb in GTP-bound stage. Indeed, this kidney AML
patient was very sensitive to mTORC1 inhibitor, everolimus.
Our report strengthens the role of TSC1/2 complex in the devel-
opment of AML and highlights the importance of TSC2mutation
as diagnostic tool or prognostic marker for renal epithelioid AML.
Normal cells require multiple mutations before they pro-
gress into uncontrolled malignant cells.27 Indeed, we found
Figure 4. CT scan before and after everolimus uptake. (a) On 17 December 2018, CT scan showed that the size of the tumor was 12.74 × 8.47 cm. (b) After 1 month
of everolimus uptake on 5 February 2018, CT scan showed that the size of the tumor was 9.46 × 5.12 cm. (c) After 2 months of everolimus uptake on 26 March 2018,
CT scan showed that the size of the tumor was 8.91 × 4.81 cm. (d) After 4 months of everolimus uptake on 21 May 2018, CT scan showed that the size of the tumor
was 8.25 × 4.6 cm.
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there was a mutation in LRP1B (c.6419G>A). LRP1B (low-
density lipoprotein receptor-related protein 1B) encodes
a surface lipoprotein, which plays a role in endocytosis by
binding and internalizing ligands.28,29 As a tumor suppressor,
the mutations of LRP1B have been widely reported in various
cancers including lung cancer, skin cancer, and stomach
cancer.29-31 However, AML with LRP1B mutation has not
been reported previously. Our report may build rational to
further develop LRP1B mutation as either diagnostic marker
or therapeutic target for AML.
In conclusion, we are the first to describe two novel mutations
of TSC2 in Chinese kidney AML-bearing patient (c2652C>A;
c2688G>A), leading to the activation of mTORC1 signaling.
Our present findings have important implications for the elucida-
tion of the pathogenic mechanisms underlying kidney AML.
Clinically, it provides a basis for the treatment of kidney AML
patients.
Disclosure of Potential Conflicts of Interest
The authors declare that there is no conflict of interest that
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Figure 5. Symptoms of anemia, white blood cells and Platelets were significantly improved after everolimus administration. (a) Red cell mass (*1012/L) level increased
and returned to normal level after everolimus uptake. (b) Hemoglobin (g/L) level increased and returned to normal level after everolimus uptake. (c) HCT level
increased and returned to normal level after everolimus uptake. (d) white blood cells (*1012/L) level decreased and returned to normal level after everolimus uptake.
(e) Platelets (*1012/L) level decreased and returned to normal level after everolimus uptake.
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